SubsidieMeesters logoSubsidieMeesters
ProjectenRegelingenAnalyses

Inhibitor-Mediated Programming of Glycoforms

The project aims to revolutionize glycan manipulation using Inhibitor-Mediated Programming of Glycoforms (IMProGlyco) to create precision-engineered therapeutic proteins and enhance cellular functions.

Subsidie
€ 2.998.878
2025

Projectdetails

Introduction

Site-directed mutagenesis revolutionised the study of proteins and enabled the development of protein-based therapeutics. Our long-term vision is to have equivalent impact through the precise manipulation of the glycans (carbohydrates) on cells and recombinant proteins that will enable the discovery and production of the next generation of therapies for cancer, neurodegeneration, and other disease families.

Importance of Glycans

The glycans that are present on most proteins and cells have a substantial impact on their biological functions. However, the untemplated nature of their synthesis leads to inherent heterogeneity in both their structure and activity. This heterogeneity is very difficult to control, making it impossible to generate defined glycan ensembles with optimal activity using current technology.

New Approach

Here we present a radically new approach to the controlled manipulation of glycans that will be the functional equivalent of site-directed mutagenesis for manipulating proteins.

Methodology

We will use the delivery of computationally defined mixtures of enzyme-specific inhibitors to the site of glycan biosynthesis in the cell to tune the activity of glycosyltransferases. Our approach, termed Inhibitor-Mediated Programming of Glycoforms (IMProGlyco), will provide an effective strategy to manipulate the glycosylation machinery and thereby generate proteins with defined ensembles of glycans.

Applications

This technology will enable the production of precision glycan-engineered therapeutic proteins and vaccines. Moreover, shaping cellular glycan profiles will aid discovery science to uncover glycan functions and improve therapeutic cells, such as those used in Chimeric Antigen Receptors cell Therapy (CAR-T).

Future Prospects

Our technology will be adaptable and expandable into other cell types and organisms, allowing glycan shaping in all areas of eukaryotic cell biology to enable new biotechnological applications and fundamental studies of biology.

Financiële details & Tijdlijn

Financiële details

Subsidiebedrag€ 2.998.878
Totale projectbegroting€ 2.998.878

Tijdlijn

Startdatum1-2-2025
Einddatum31-1-2028
Subsidiejaar2025

Partners & Locaties

Projectpartners

  • UNIVERSITY OF LEEDSpenvoerder
  • UNIVERSITY OF YORK
  • UNIVERSITAET FUER BODENKULTUR WIEN
  • OSLOMET - STORBYUNIVERSITETET
  • OSLO UNIVERSITETSSYKEHUS HF
  • GLYCOSELECT LTD
  • CENTRE FOR PROCESS INNOVATION LIMITED LBG

Land(en)

United KingdomAustriaNorwayIreland

Inhoudsopgave

EIC Pathfinder

Financiering tot €3–4 mln voor high‑risk, high‑gain onderzoek naar baanbrekende technologieën binnen Horizon Europe.

Bekijk regeling

Vergelijkbare projecten binnen EIC Pathfinder

ProjectRegelingBedragJaarActie

Functional chemical reprogramming of cancer cells to induce antitumor immunity

The RESYNC consortium aims to revolutionize cancer immunotherapy by reprogramming cancer cells into antigen-presenting dendritic cells using small molecules for personalized and safer treatments.

EIC Pathfinder€ 2.966.695
2024
Details

Understanding the potential of modulating Host-Microbiome-Glycan interactions (“the triangle of sweetness”) to tackle non-communicable diseases

The project aims to identify novel glycosyltransferases and HMOs, analyze their gut interactions, and validate an HMO for inflammation relief, enhancing glycobiology research and therapeutic applications.

EIC Pathfinder€ 3.920.718
2024
Details
EIC Pathfinder

Functional chemical reprogramming of cancer cells to induce antitumor immunity

The RESYNC consortium aims to revolutionize cancer immunotherapy by reprogramming cancer cells into antigen-presenting dendritic cells using small molecules for personalized and safer treatments.

EIC Pathfinder
€ 2.966.695
2024
Details
EIC Pathfinder

Understanding the potential of modulating Host-Microbiome-Glycan interactions (“the triangle of sweetness”) to tackle non-communicable diseases

The project aims to identify novel glycosyltransferases and HMOs, analyze their gut interactions, and validate an HMO for inflammation relief, enhancing glycobiology research and therapeutic applications.

EIC Pathfinder
€ 3.920.718
2024
Details

Vergelijkbare projecten uit andere regelingen

ProjectRegelingBedragJaarActie

Precision control of glycosylation to open a new era of therapeutic antibodies

GlycoBoost aims to revolutionize monoclonal antibody design by producing therapeutics with uniform N-glycans, enhancing safety and efficacy for autoimmune disease treatments.

EIC Transition€ 2.499.540
2025
Details

Isotopically labelling of cell surface glycans to illuminate infectious processes at atomic resolution

Glyco13Cell aims to chemically remodel cell surface glycans using NMR probes to enhance understanding of glycan-lectin interactions for developing novel tools in infectious disease treatment.

ERC Starting...€ 1.500.000
2023
Details

Engineering CAR-T cells to overcome glycosylation-driven tumour resistance

The project aims to engineer CAR-T cells that express an enzyme to de-glycosylate tumor cells, enhancing their efficacy against solid cancers by overcoming immunosuppressive barriers.

ERC Starting...€ 1.500.000
2023
Details

Glycan Mimetics for Cell Glycocalyx Reconstitution: a polymer chemist’s approach to fight infection

GLYMCE aims to uncover how carbohydrates influence pathogen interactions to create innovative glycopolymer materials for infection prevention and treatment.

ERC Consolid...€ 1.994.024
2024
Details

A general approach for the design of covalent protein proximity inducers

This project aims to expand biochemical perturbations using CoLDR chemistry to create small molecules that activate enzymes, modify PTMs, and control protein interactions for therapeutic applications.

ERC Consolid...€ 1.998.744
2024
Details
EIC Transition

Precision control of glycosylation to open a new era of therapeutic antibodies

GlycoBoost aims to revolutionize monoclonal antibody design by producing therapeutics with uniform N-glycans, enhancing safety and efficacy for autoimmune disease treatments.

EIC Transition
€ 2.499.540
2025
Details
ERC Starting...

Isotopically labelling of cell surface glycans to illuminate infectious processes at atomic resolution

Glyco13Cell aims to chemically remodel cell surface glycans using NMR probes to enhance understanding of glycan-lectin interactions for developing novel tools in infectious disease treatment.

ERC Starting Grant
€ 1.500.000
2023
Details
ERC Starting...

Engineering CAR-T cells to overcome glycosylation-driven tumour resistance

The project aims to engineer CAR-T cells that express an enzyme to de-glycosylate tumor cells, enhancing their efficacy against solid cancers by overcoming immunosuppressive barriers.

ERC Starting Grant
€ 1.500.000
2023
Details
ERC Consolid...

Glycan Mimetics for Cell Glycocalyx Reconstitution: a polymer chemist’s approach to fight infection

GLYMCE aims to uncover how carbohydrates influence pathogen interactions to create innovative glycopolymer materials for infection prevention and treatment.

ERC Consolidator Grant
€ 1.994.024
2024
Details
ERC Consolid...

A general approach for the design of covalent protein proximity inducers

This project aims to expand biochemical perturbations using CoLDR chemistry to create small molecules that activate enzymes, modify PTMs, and control protein interactions for therapeutic applications.

ERC Consolidator Grant
€ 1.998.744
2024
Details

SubsidieMeesters logoSubsidieMeesters

Vind en verken subsidieprojecten in Nederland en Europa.

Links

  • Projecten
  • Regelingen
  • Analyses

Suggesties

Heb je ideeën voor nieuwe features of verbeteringen?

Deel je suggestie
© 2025 SubsidieMeesters. Alle rechten voorbehouden.